KOrea COpd Subgroup Registry and Subtype Research

• Conditions: COPD

• Registration Number: NCT02800499
• Lead Sponsor: Konkuk University Medical Center

Brief Summary

The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional and observational study within the Korean COPD patients. The prevalence of early COPD (mild to moderate COPD based by 2011 GOLD(the Global Initiative for Chronic Obstructive Lung Disease) guideline) is high in Korea. However, the patients with early COPD are not underdiagnosed due to mild symptom. The purpose of this study is to investigate early COPD characteristics and disease course and to form a guideline for early detection of COPD patients and prevention of progression to severe COPD.

Detailed Description

This study is a multicentered, observational study of the patients with COPD who were enrolled in 45 tertiary and university-affiliated hospitals from December 2012 to now.

The initial evaluation for all patients includes pulmonary function tests (PFT), 6-min walk distance (6MWD), COPD Assessment Test (CAT), modified Medical Research Council (mMRC) dyspnea scale, and the COPD-specific version of St. George's Respiratory Questionnaire (SGRQ-C), exacerbations in the previous 12 months, smoking status, patient-reported education level, medications and comorbidities.

Pulmonary function tests (PFTs) are performed every 6 months and CAT, mMRC and SGRQ-C are evaluated every 6 months and 6 min walt test is performed every years during the whole period of study.

All of the data were reported using case-report forms (CRFs) which are completed by physicians or trained nurses, and the patients are to be evaluated at regular 6-month intervals after the initial examination.

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2016-06-04
• Study First Submitted QC: 2016-06-09
• Study First Posted: 2016-06-15
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-04
• Last Update Posted: 2024-03-06
• Primary Completion: 2042-02
• Study Completion: 2042-02

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Over 40 years old South Korean COPD patients(Bronchodilator test results FEV1/FVC <0.7)
• COPD patients who complain of cough, sputum, dyspnea
• Unrelated smoking history

Exclusion Criteria

• other disease like asthma patients which is similar to COPD symptoms.
• patients who is not suitable for pulmonary function test and communication
• myocardial infarction or cerebrovascular event within the previous 3 months
• pregnants
• patients who disagree with registration
• rheumatoid patients
• cancer patients(including metastatic cancer, leukemia, lymphoma)
• irritable bowel syndrome
• patients who use systemic steroids over 8 weeks due to other diseases except COPD

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of acute exacerbation	5 years	Number of events

Secondary Outcome Measures

Name	Time	Method
COPD Treatment	Through study completion, average 5 years	COPD treatments are defined as inhaled therapies, oral therapies and other therapies administered during the enrollment and influenza vaccination and smoking cessation therapy
Pulmonary function tests	5 years	COPD severity will be assessed based on post-bronchodilator Forced expiratory volume in one second(FEV) and FEV1/FVC(Forced vital capacity). FEV1 to forced vital capacity (FVC) :Mild - FEV1/FVC\<0.7, FEV1 ≥80% normal Moderate - FEV1/FVC\<0.7, FEV1 50-79% normal; Severe - FEV1/FVC\<0.70, FEV1 30-49% normal; Very Severe - FEV1/FVC\<0.70, FEV1 \<30% predicted. We will measure spirometry at screening and every 6 months.
Modified Medical Research Council [mMRC] dyspnea scale	5 years	mMRC dyspnea scale is five-point scale with higher scores indicating more severe dyspnea. We will assess mMRC at screening and every 6 months.
6-min walk distance (6MWD)	5 years	The 6MWD has been used as a simple tool to assess overall exercise tolerance in COPD patients. We will measure 6 min walk distance by ATS guideline at screening and every 6 months during the follow-up period
the COPD-specific version of St. George's Respiratory Questionnaire (SGRQ-C)	5 years	to assess the health status from the patient's perspective .The SGRQ-C is a 14-item questionnaire that can be summarized as a total score, as well as by three component scores for symptoms, activities, and impacts. We will assess SGRQ at screening and every 6 months.
Percentage of Participants with smoking history	5 years	we will assess smoking history at screening and every 6 months
Percentage of Participants with Other Relevant Diseases	5 years	We will examine the relevant disease which is defined as respiratory diseases, cardiovascular diseases (ischaemic heart disease, heart failure, hypertension), and other diseases (osteoporosis, GERD(gastroesophageal reflux disease), hyperlipidemia, bronchiectasis, emphysema).
COPD Assessment Test (CAT)	5 years	The CAT score was also used for evaluation of dyspnea. It consists of 8 items, each scored from 0 to 5, with higher scores indicating a more severe symptom.We will measure CAT at screening and every 6 months.

Trial Locations

Locations (1)

Konkuk University Hospital; 🇰🇷 Seoul, Korea, Republic of